Phase 3 N=244 Improving Insulin Therapy With Enhanced Care Management
Diabetes
Primary: Change in Glycemic Control (HbA1c) — 8.02; 7.93; 7.73; 8.22 percent HbA1c — p=0.004
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=602 Effect of Body Weight Change to Surgical ICU Outcomes
Body Weight · Weight Change
Primary: In Hospital Mortality — 52; 44 participants
Phase 4 N=114 Argatroban for Preventing Occlusion and Restenosis After Intracranial and Extracranial Artery Stenting
CVD
Primary: Number of Participants With Occlusion and Restenosis at One Year — 58; 56 participants
Phase 2 N=58 OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control Rate at 12 Weeks — 6; 6 participants
Phase 1 N=13 The Boceprevir and Sildenafil Pharmacokinetics Study
Hepatitis C
Primary: Sildenafil Alone Maximum Plasma Concentration — 79.9 ng/mL
Phase 3 N=1,105 Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Major Depressive Disorder
Primary: Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks — -7.3; -6.8 units on a scale — p=0.583
Phase 3 N=335 A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa Therapies
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20 (ACR20) Response — 67.5; 74.9; 73.9; 67.4 Percentage of participants
N/A N=8 Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Aromatase Inhibitor Therapy
Male Breast Cancer · Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Rate of Clinical Benefit According to RECIST — 15 percentage of evaluable participants
Phase 4 N=60 Does Preop Midazolam Maintain Blood Glucose Norms in the Non Diabetic Perioperative Period
Hernia
Primary: Maximum Perioperative Blood Glucose Level of 30 Minute Interval Measurements — 114.0; 108.0 mg/dL — p=0.87
Phase 2 N=7 IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia
Von Willebrand Disease
Primary: >50% Reduction in PBAC (Pictorial Blood Assessment Chart) at 6 Months — 71 percentage of participants
Phase 3 N=195 Re-Engineering Systems for the Primary Care Treatment for PTSD
Stress Disorders, Posttraumatic · Depression
Primary: PTSD Symptom Severity — 31.4; 31.5; 30.2; 29.9 units on a scale
N/A N=96 Post-Op Rotator Cuff Pain Study With Subacromial Bupivacaine Infusion
Rotator Cuff Tear
Primary: Pain Scores — 64.7; 43.9; 51.4; 60 mm
Phase 2 N=30 Diabetes in Neuropsychiatric Disorders
Schizophrenia
Primary: Body Mass Index — 22.1; 23.5; 24.2; 24.3 kg/m^2 — p=<0.001
Phase 3 N=724 Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
HIV Infection
Primary: Percentage of Participants Achieving and Maintaining Confirmed HIV-1 RNA < 50 Copies/mL at Week 48 — 59.0; 57.8 percentage of participants
Phase 3 N=15 A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy
Rheumatoid Arthritis
Primary: Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24 — 2.98 score on a scale — p=<0.001